These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

86 related items for PubMed ID: 11219309

  • 21. [How well do gyrase inhibitors work? The pharmacokinetics of quinolones].
    Sörgel F, Bulitta J, Kinzig-Schippers M.
    Pharm Unserer Zeit; 2001; 30(5):418-27. PubMed ID: 11575179
    [No Abstract] [Full Text] [Related]

  • 22. [Fluoroquinolones (gyrase inhibitors)].
    Senf HJ.
    Pharmazie; 1988 Jun; 43(6):444-7. PubMed ID: 2850589
    [No Abstract] [Full Text] [Related]

  • 23. [Fluoroquinolones].
    Lumio J.
    Duodecim; 1991 Jun; 107(10):757-64. PubMed ID: 1364719
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates.
    Montanari MP, Mingoia M, Varaldo PE.
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3616-22. PubMed ID: 11709353
    [Abstract] [Full Text] [Related]

  • 26. In vitro evaluation of lomefloxacin (NY-198 or SC-47111), a new difluoro-quinolone.
    Jones RN.
    J Chemother; 1989 Jul; 1(4 Suppl):165-7. PubMed ID: 16312353
    [No Abstract] [Full Text] [Related]

  • 27. Advances in the macrolides and quinolones.
    Boswell FJ, Wise R.
    Infect Dis Clin North Am; 1998 Sep; 12(3):647-70. PubMed ID: 9779383
    [Abstract] [Full Text] [Related]

  • 28. [Quinolones in the environment: biological breakdown of gyrase inhibitors].
    Wetzstein HG.
    Pharm Unserer Zeit; 2001 Sep; 30(5):450-7. PubMed ID: 11575183
    [No Abstract] [Full Text] [Related]

  • 29. Resistance to quinolones in mycobacteria.
    Cambau E, Jarlier V.
    Res Microbiol; 1996 Sep; 147(1-2):52-9. PubMed ID: 8761723
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. In vitro antimicrobial activity of lomefloxacin against staphylococci, enterococci, and Enterobacteriaceae.
    Rossolini GM, Valentini S, Vaiani G, Satta G.
    J Chemother; 1989 Jul; 1(4 Suppl):173-6. PubMed ID: 16312356
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Is the penicillin and pneumococcal model transferable to the new quinolones?].
    Mainardi JL.
    Rev Pneumol Clin; 2000 Oct; Suppl 1():1S24-6. PubMed ID: 11103987
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. The place of quinolones in medicine today.
    Oh HM.
    Singapore Med J; 1994 Dec; 35(6):562-4. PubMed ID: 7761876
    [No Abstract] [Full Text] [Related]

  • 37. From fluoroquinolones to 2-pyridones.
    Hooper DC.
    Lancet; 1995 May 13; 345(8959):1192-3. PubMed ID: 7739303
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. [Quinolones: significance and problems in the clinic and in general practice].
    Daschner F, Kappstein I.
    Internist (Berl); 1988 Mar 13; 29(3):206-12. PubMed ID: 2837440
    [No Abstract] [Full Text] [Related]

  • 40. Gram-positive infections and quinolones in neutropenia.
    Castagnola E, Viscoli C.
    Ann Intern Med; 1997 May 15; 126(10):830-1. PubMed ID: 9148666
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.